RVNC Insider Trading
Insider Ownership Percentage: 5.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Revance Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Revance Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Revance Therapeutics Share Price & Price History
Current Price: $3.65
Price Change: +0.30 (1.20%)
As of 02/6/2025 01:00 AM ET
Revance Therapeutics Insider Trading History
Revance Therapeutics Institutional Trading History
Data available starting January 2016
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Read More on Revance Therapeutics
Volume
N/A
Average Volume
3,294,454 shs
Market Capitalization
$381.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.9
Who are the company insiders with the largest holdings of Revance Therapeutics?
Who are the major institutional investors of Revance Therapeutics?
Which major investors are selling Revance Therapeutics stock?
During the last quarter, RVNC stock was sold by these institutional investors:
- Wolverine Asset Management LLC